Cloning of hexamethylene-bis-acetamide-inducible transcript, HEXIM1, in human vascular smooth muscle cells

Biomedical Research

Volumn 20, Issue 5, 1999, Pages 273-279

  Kusuhara, Masatoshi ^a   Nagasaki, Koichi ^b   Kimura, Kensuke ^c   Maass, Nicolai ^b   Manabe, Tomohiro ^c   Ishikawa, Shiro ^c   Aikawa, Minoru ^a   Miyazaki, Koji ^b   Yamaguchi, Ken ^b  

^a Yokohama Stroke and Brain Center ^*  (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; HEXAMETHYLENEBISACETAMIDE; MESSENGER RNA;

ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CONTROLLED STUDY; CORONARY ARTERY; GENE EXPRESSION; GENE ISOLATION; HUMAN; HUMAN CELL; MESSENGER RNA SYNTHESIS; MOLECULAR CLONING; NORTHERN BLOTTING; SCREENING; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

EUKARYOTA;

EID: 0033501002     PISSN: 03886107     EISSN: None     Source Type: Journal    
DOI: 10.2220/biomedres.20.273     Document Type: Article

References (28)

1. Campbell G. R. and Campbell J. H. (1985) Smooth muscle phenotypic changes in arterial wall homeostasis: implications for the pathogenesis of atherosclerosis. Exp. Mol. Pathol. 42, 139-162.
2. Campbell J. H. and Campbell G. R. (1994) The role of smooth muscle cells in atherosclerosis. Curr. Opin. Lipidol. 5, 323-330.
3. Drab M., Haller H., Bychkov R., Erdmann B., Lindschau C., Haase H., Morano I., Luft F. C. and Wobus A. M. (1997) From totipotent embryonic stem cells to spontaneously contracting smooth muscle cells: a retinoic acid and db-cAMP in vitro differentiation model. FASEB J. 11, 905-915.
4. Gordon D. and Rekhter M. D. (1997) The growth of human atherosclerosis: cell proliferation and collagen synthesis. Cardiovasc. Pathol. 6, 103-116.
5. Grainger D. J., Hesketh T. R., Weissberg P. L. and Metcalfe J. C. (1992) Hexamethylenebisacetamide selectively inhibits the proliferation of human and rat vascular smooth-muscle cells. Biochem. J. 283, 403-408.
6. Hultgardh-Nilsson A., Lovdahl C., Blomgren K., Kallin B. and Thyberg J. (1997) Expression of phenotype-and proliferation-related genes in rat aortic smooth muscle cells in primary culture. Cardiovasc. Res. 34, 418-430.
7. Ishikawa S., Hod S., Kusuhara M., Kanai Y., Manda S., Yamaguchi K., Hosoda Y. and Ogawa S. (1997) Differentiating agent, hexamethylene bisacetamide, inhibits neointimal formation after vascular injury. Coron. Artery Dis. 8, 28-32.
8. Kemp P. R., Metcalfe J.C. and Grainger D. J. (1995) ID - a dominant negative regulator of skeletal muscle differentiation - is not involved in maturation or differentiation of vascular smooth muscle cells. FEBS Lett. 368, 81-86.
9. Kozak M. (1984) Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs. Nucleic Acids Res. 12, 857-872.
10. Kozak M. (1987) An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. 15, 8125-8148.
11. Laborda J. (1991) 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res. 19, 3998.
12. Liang P. and Pardee A. B. (1992) Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 257, 967-971.
13. Liau G., Chan L. M. and Feng P. (1991) Increased ferritin gene expression is both promoted by cAMP and a marker of growth arrest in rabbit vascular smooth muscle cells. J. Biol. Chem. 266, 18819-18826.
14. Majesky M. W., Giachelli C. M., Reidy M. A. and Schwartz S. M. (1992) Rat carotid neointimal smooth muscle cells reexpress a developmentally regulated mRNA phenotype during repair of arterial injury. Circ. Res. 71, 759-768.
15. MasiakowskiA P., Breathnach R., Bloch L J., Gannon F., Krust A. and Chambon P. (1982) Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res. 10, 7895-7903.
16. Mosse P. R., Campbell G. R., Wang Z. L. and Campbell J. H. (1985) Smooth muscle phenotypic expression in human carotid arteries I. Comparison of cells from diffuse intimal thickenings adjacent to atheromatous plaques with those of the media. Lab. Invest. 53, 556-562.
17. Nagasaki K., Maass N., Manabe T., Hanzawa H., Tsukada T., Kikuchi K. and Yamaguchi K., (1999) Identification of a novel gene, DAM1, amplified at chromosome 1 p13.3-21 in human breast cancer. Cancer Lett. 140 219-226 (1999).
18. Nagasaki K., Manabe T., Hanzawa H., Maass N., Tsukada T. and Yamaguchi K. (1999) Identification of a novel gene, LDOC1, down-regulated in cancer cell lines. Cancer Lett. 140 227-234 (1999).
19. Owens G. K. (1995) Regulation of differentiation of vascular smooth muscle cells. Physiol. Rev. 75, 487-517.
20. Parker T. G. and Schneider M. D. (1991) Growth factors, proto-oncogenes, and plasticity of the cardiac phenotype. Annu. Rev. Physiol. 53, 179-200.
21. Reuben R. C., Wife R L., Breslow R., Rifkind R. A. and Marks P. A. (1976) A. new group of potent inducers of differentiation in marine erythroleukemia cells. Proc. Natl. Acad. Sci. USA 73, 862-866.
22. Ross R. (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362, 801-809.
23. Sassoon D. A. (1993) Myogenic regulatory factors: dissecting their role and regulation during vertebrate embryogenesis. Dev. Biol. 156, 11-23.
24. Schwartz S. M., Campbell G. R. and Campbell J. H. (1986) Replication of smooth muscle cells in vascular disease. Circ. Res. 58, 427-444.
25. Schwartz S. M., deBlois D, and O'Brien E. R. (1995) The intima. Soil for atherosclerosis and restenosis. Circ. Res. 77, 445-465.
26. Schwartz S. M., Heimark R. L. and Majesky M. W. (1990) Developmental mechanisms underlying pathology of arteries. Physiol. Rev. 70, 1177-1209.
27. Thyberg J. Hultgardh-Nilsson A, and Kallin B (1995) Inhibitors of ADP-ribosylation suppress phenotypic modulation and proliferation of smooth muscle cells cultured from rat aorta. Differentialion 59, 243-252.
28. Young C. W., Fanucchi M. P., Declan Walsh T., Baltzer L., Yaldaei S., Stevens Y. W., Gordon C., Tong W., Rifkind R. A., and Marks P. A.(1988) Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenly-eight-day intervals. Cancer Res. 48, 7304-7309.